Nektar Therapeutics
POLYMER-SEMAXANIB MOIETY CONJUGATES
Last updated:
Abstract:
The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
Status:
Application
Type:
Utility
Filling date:
3 Oct 2019
Issue date:
30 Jan 2020